MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial

Rodriguez, Daniel; Calmon, Raphael; Aliaga, Esther Sanchez; Warren, Daniel; Warmuth-Metz, Monika; Jones, Chris; Mackay, Alan; Varlet, Pascale; Le Deley, Marie Cécile; Hargrave, Darren; Cañete, Adela; Massimino, Maura; Azizi, Amedeo A.; Saran, Frank; Zahlmann, Gudrun; Garcia, Josep; Vassal, Gilles; Grill, Jacques; Peet, Andrew; Dineen, Robert A.; Morgan, Paul S.; Jaspan, Timothy

doi:10.1148/radiol.211464

All Outputs (2)

Recurrent ACVR1 mutations in posterior fossa ependymoma (2022)
Journal Article
Pratt, D., Lucas, C.-H. G., Selvam, P. P., Abdullaev, Z., Ketchum, C., Quezado, M., …Aldape, K. (2022). Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta Neuropathologica, 144, 373-376. https://doi.org/10.1007/s00401-022-02435-2

MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial (2022)
Journal Article
Rodriguez, D., Calmon, R., Aliaga, E. S., Warren, D., Warmuth-Metz, M., Jones, C., …Jaspan, T. (2022). MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. Radiology, 304(1), 174-182. https://doi.org/10.1148/radiol.211464

Background Diffuse midline gliomas (DMG) are characterized by a high incidence of H3 K27 mutations and poorer outcome. The HERBY trial has provided one of the largest cohorts of pediatric DMGs with available radiologic, histologic-genotypic, and surv... Read More about MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.